Drug intelligence / Profile preview

IMM47

Development stage: Phase 1
Lead developer: Immunova Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

IMM47 is an iNKT cell agonist being developed by IOX Therapeutics. It is intended for the treatment of diseases such as cancer. The underlying technology for IMM47 was discovered through a collaborative partnership between the Ludwig Institute and the University of Oxford.

Targets

CD24 (Cluster of Differentiation 24)

Beyond the preview

Go deeper on IMM47.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMM47.

Explore the full profile